Orchard Therapeutics has appointed Jon Ellis as GSK’s designated representative to its board of directors, following GSK’s sale of its rare disease gene therapy programmes to the company. Jon is currently vice president and head of science & technology licensing at GlaxoSmithKline (GSK). He brings more than 25 years experience in the pharmaceutical and biotech industry, leading a variety of R&D activities including drug development projects and strategic business development with a particular focus on complex technologies and emerging therapeutic modalities. At GSK, Jon led several strategic transactions in the gene therapy field.
“GSK conducted an exhaustive process to identify the best company to place its gene therapy programmes for rare diseases. Orchard impressed us with its commitment and capabilities. I am delighted to be joining Orchard’s board of directors and look forward to working with the board and executive team to deliver commercially approved gene therapies to patients across the world.”
